Results 31 to 40 of about 644,115 (313)
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors
New England Journal of Medicine, 2019 Background Andexanet alfa is a modified recombinant inactive form of human factor Xa developed for reversal of factor Xa inhibitors. Methods We evaluated 352 patients who had acute major bleeding within 18 hours after administration of a factor Xa ...
S. Connolly +28 more
semanticscholar +1 more source
Journal of Neurology, 2020 Background Oral Factor Xa inhibitors for the prevention of stroke in atrial fibrillation require dose adjustment based on certain clinical criteria, but the off-label use of the reduced doses is common.
Svenja Stoll +9 more
semanticscholar +1 more source
, 2016 Factor Xa represents an attractive target for antithrombotic drugs as blockade of factor Xa permits inhibition of both the extrinsic and intrinsic coagulation pathways. Several factor Xa inhibitors, such as rivaroxaban, apixaban and edoxaban, have been approved for certain conditions, and are also in clinical development for other indications.
Gregory Y.H. Lip, Eduard Shantsila
openaire +2 more sources
Oral Direct Factor Xa Inhibitors [PDF]
Circulation Research, 2012 Vitamin K antagonists, such as warfarin, have been the mainstay of oral anticoagulation for many decades. Although effective, warfarin has numerous limitations, including a variable dose requirement from patient to patient because of differences in dietary vitamin K intake, common genetic polymorphisms, and multiple drug interactions that affect its ...
Jeffrey I. Weitz +2 more
openaire +2 more sources
Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management [PDF]
, 2017 Novel oral anticoagulants (NOACs), which include direct thrombin inhibitor (dabigatran) and direct factor Xa inhibitors (rivaroxaban, apixaban and edoxaban), are gaining popularity in the prevention of embolic stroke in non-valvular atrial fibrillation ...
Cheung, KS, Leung, WK
core +1 more source
Рациональная фармакотерапия в кардиологии, 2017 Aim. To study the initial disorders in the coagulation system, as factors influencing the development of bleeding during anticoagulant therapy with direct oral anticoagulants (DOAC).Material and methods.
A. А. Sokolova +4 more
doaj +1 more source
British Journal of Clinical Pharmacology, 2020 Using 3 different perpetrators the impact of voriconazole, cobicistat and rifampicin (single dose), we evaluated the suitability of a microdose cocktail of factor Xa inhibitors (FXaI; rivaroxaban, apixaban and edoxaban; 100 μg in total) to study drug ...
G. Mikus +5 more
semanticscholar +1 more source
Gla-domainless factor Xa: molecular bait to bypass a blocked tenase complex
Haematologica, 2012 Background Hemophilia is caused by deficiencies in coagulation factor VIII or IX, resulting in direct blockade of the intrinsic tenase complex and indirect blockade of the extrinsic tenase complex which is rapidly inhibited upon binding of factor Xa to ...
Raphaël Marlu, Benoît Polack
doaj +1 more source
How we treat bleeding associated with direct oral anticoagulants [PDF]
, 2016 Direct oral anticoagulants are at least as effective as vitamin K antagonists for the prevention and treatment of thromboembolism. Unfortunately, differently from vitamin K antagonists, they have the great drawback of lacking specific antidotes in the ...
Franchini, Massimo +4 more
core +1 more source
Evolutionary dynamics on a regular networked structured and unstructured multi‐population
International Journal of Robust and Nonlinear Control, EarlyView., 2023 Abstract In this paper, we study collective decision‐making in a multi‐population framework, where groups of individuals represent whole populations that interact by means of a regular network. Each group consists of a number of players and every player can choose between two options.
Wouter Baar +2 more
wiley +1 more source